Combination therapy targeting hypoxia inducible factor-α ( HIF-1 α) and Tissue Factor (TF) by the mTOR inhibitor Rapamycin and the histone deacetylase inhibitor LBH589

被引：0
|
作者：
Verheul, Henk M. W.
Qian, David Z.
Van Erp, Karen
Salumbides, Brenda
Sanni, Tolib
Atadja, Peter
Pili, Roberto
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Novartis Inst Biomed Res, E Hanover, NJ USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1033
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells
    Xiao, Weiwei
    Graham, Peter H.
    Hao, Jingli
    Chang, Lei
    Ni, Jie
    Power, Carl A.
    Dong, Qihan
    Kearsley, John H.
    Li, Yong
    PLOS ONE, 2013, 8 (08):
  • [2] Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor dependent human lung cancer cells
    Haura, E.
    Edwards, A.
    Bhalla, K.
    EJC SUPPLEMENTS, 2006, 4 (12): : 182 - 183
  • [3] Targeting hypoxia inducible factor 1 (HIF-1) for cancer therapy
    Melillo, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 23 - 23
  • [4] Combination strategy targeting the hypoxia inducible factor-1α with mammalian target of rapamycin and histone deacetylase inhibitors
    Verheul, Henk M. W.
    Salumbides, Brenda
    Van Erp, Karen
    Hammers, Hans
    Qian, David Z.
    Sanni, Tolib
    Atadja, Peter
    Pili, Roberto
    CLINICAL CANCER RESEARCH, 2008, 14 (11) : 3589 - 3597
  • [5] Paradoxical Regulation of Hypoxia Inducible Factor-1α (HIF-1α) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma
    Bhallar, Savita
    Evens, Andrew M.
    Prachandl, Sheila
    Schumacker, Paul T.
    Gordon, Leo I.
    PLOS ONE, 2013, 8 (11):
  • [6] Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells
    Edwards, Arthur
    Li, Jiannong
    Atadja, Peter
    Bhalla, Kapil
    Haura, Eric B.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (09) : 2515 - 2524
  • [7] A novel therapeutic combination with synergistic antitumor activity in colon cancer: The dual tyrosine kinase inhibitor lapatinib and the histone deacetylase inhibitor LBH589
    LaBonte, Melissa J.
    Wilson, Peter M.
    El-Khoueiry, Anthony
    Lenz, Heinz -Josef
    Ladner, Robert D.
    CANCER RESEARCH, 2010, 70
  • [8] Total synthesis of verucopeptin, an inhibitor of hypoxia-inducible factor 1 (HIF-1)
    Takahashi, Nobuaki
    Hayashi, Hideaki
    Poznaks, Viktors
    Kakeya, Hideaki
    CHEMICAL COMMUNICATIONS, 2019, 55 (79) : 11956 - 11959
  • [9] The histone deacetylase inhibitor LBH589 inhibit undifferentiated pleomorphic sarcoma growth via downregulation of FOSL1
    Saitoh, Yoshinobu
    Setoguchi, Takao
    Nagano, Satoshi
    Taniguchi, Noboru
    CANCER SCIENCE, 2018, 109 : 1416 - 1416
  • [10] The contribution of hypoxia inducible factor 1 alpha (HIF-1α) to tissue factor (TF) expression in the hypoxic cancer cell.
    Khorsandi, SE
    Kakkar, AK
    BLOOD, 2001, 98 (11) : 446A - 446A
12345